Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

227 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 81,357,406 shares of 104,661,494 outstanding shares and own 77.73% of the company stock.
Largest 10 shareholders include Capital World Investors (13,938,589 shares), BlackRock Inc. (8,565,317 shares), FRANKLIN RESOURCES INC (6,258,918 shares), VANGUARD GROUP INC (5,994,459 shares), Palo Alto Investors LP (5,257,086 shares), Polar Capital Holdings Plc (3,567,139 shares), JPMORGAN CHASE & CO (2,944,861 shares), Stonepine Capital Management, LLC (2,800,000 shares), Rubric Capital Management LP (2,656,847 shares), and GEODE CAPITAL MANAGEMENT, LLC (2,297,965 shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.